These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24398694)

  • 41. Partially crystalline systems in lyophilization: I. Use of ternary state diagrams to determine extent of crystallization of bulking agent.
    Chatterjee K; Shalaev EY; Suryanarayanan R
    J Pharm Sci; 2005 Apr; 94(4):798-808. PubMed ID: 15729706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Physical state of L-histidine after freeze-drying and long-term storage.
    Osterberg T; Wadsten T
    Eur J Pharm Sci; 1999 Aug; 8(4):301-8. PubMed ID: 10425380
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thermophysical properties of pharmaceutically compatible buffers at sub-zero temperatures: implications for freeze-drying.
    Shalaev EY; Johnson-Elton TD; Chang L; Pikal MJ
    Pharm Res; 2002 Feb; 19(2):195-201. PubMed ID: 11883647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation of histidine stabilizing effects on LDH during freeze-drying.
    Al-Hussein A; Gieseler H
    J Pharm Sci; 2013 Mar; 102(3):813-26. PubMed ID: 23280685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of freezing procedure and annealing on the physico-chemical properties and the formation of mannitol hydrate in mannitol-sucrose-NaCl formulations.
    Hawe A; Friess W
    Eur J Pharm Biopharm; 2006 Nov; 64(3):316-25. PubMed ID: 16875806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Raffinose crystallization during freeze-drying and its impact on recovery of protein activity.
    Chatterjee K; Shalaev EY; Suryanarayanan R
    Pharm Res; 2005 Feb; 22(2):303-9. PubMed ID: 15783079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the physical stability of freeze-dried sucrose-containing formulations by differential scanning calorimetry.
    te Booy MP; de Ruiter RA; de Meere AL
    Pharm Res; 1992 Jan; 9(1):109-14. PubMed ID: 1589394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Succinate Buffer in Biologics Products: Real-world Formulation Considerations, Processing Risks and Mitigation Strategies.
    Ukidve A; Rembert KB; Vanipenta R; Dorion P; Lafarguette P; McCoy T; Saluja A; Suryanarayanan R; Patke S
    J Pharm Sci; 2023 Jan; 112(1):138-147. PubMed ID: 35667631
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of Formulation and Process Parameters on the Disproportionation of Indomethacin Sodium in Buffered Lyophilized Formulations.
    Koranne S; Thakral S; Suryanarayanan R
    Pharm Res; 2018 Jan; 35(1):21. PubMed ID: 29305664
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protein Aggregation in Frozen Trehalose Formulations: Effects of Composition, Cooling Rate, and Storage Temperature.
    Connolly BD; Le L; Patapoff TW; Cromwell MEM; Moore JMR; Lam P
    J Pharm Sci; 2015 Dec; 104(12):4170-4184. PubMed ID: 26398200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Influence of Mannitol Hemihydrate on the Secondary Drying Dynamics of a Protein Formulation: A Case Study.
    Srinivasan JM; Wegiel LA; Hardwick LM; Nail SL
    J Pharm Sci; 2017 Dec; 106(12):3583-3590. PubMed ID: 28867201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinetics of glycine crystallization during freezing of sucrose/glycine excipient systems.
    Li X; Nail SL
    J Pharm Sci; 2005 Mar; 94(3):625-31. PubMed ID: 15666294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying.
    Sarciaux JM; Mansour S; Hageman MJ; Nail SL
    J Pharm Sci; 1999 Dec; 88(12):1354-61. PubMed ID: 10585234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Method development and analysis of the water content of the maximally freeze concentrated solution suitable for protein lyophilisation.
    Seifert I; Bregolin A; Fissore D; Friess W
    Eur J Pharm Biopharm; 2020 Aug; 153():36-42. PubMed ID: 32526356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of mannitol crystallization in mannitol-sucrose systems on LDH stability during freeze-drying.
    Al-Hussein A; Gieseler H
    J Pharm Sci; 2012 Jul; 101(7):2534-44. PubMed ID: 22535541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems.
    Pikal-Cleland KA; Cleland JL; Anchordoquy TJ; Carpenter JF
    J Pharm Sci; 2002 Sep; 91(9):1969-79. PubMed ID: 12210044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Calorimetry and complementary techniques to characterize frozen and freeze-dried systems.
    Sundaramurthi P; Suryanarayanan R
    Adv Drug Deliv Rev; 2012 Apr; 64(5):384-95. PubMed ID: 22210136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying.
    Jovanović N; Bouchard A; Hofland GW; Witkamp GJ; Crommelin DJ; Jiskoot W
    Eur J Pharm Sci; 2006 Mar; 27(4):336-45. PubMed ID: 16338123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of the active pharmaceutical ingredient concentration on the physical state of mannitol--implications in freeze-drying.
    Liao X; Krishnamurthy R; Suryanarayanan R
    Pharm Res; 2005 Nov; 22(11):1978-85. PubMed ID: 16132343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.